Magen Biosciences, a Waltham, MA-based company focused on novel dermatology treatments, is acquired by the contract research firm PPD for $14.5 million December 18, 2010
Posted by HubTechInsider in Acquisitions, Biotech, Health Care IT, Pharmaceuticals, Startups.Tags: Acquisitions, Biotech, Biotechnology, Christoph Westphal, Health Care IT, IDG Ventures, Magen Biosciences, Massachusetts General Hospital, pharmaceuticals, PPD, Sirtris Pharmaceuticals, Startups, TVM Capital, waltham, Waltham Massachusetts
trackback
Magen Biosciences, a Waltham, MA-based company focused on novel dermatology treatments, will be acquired by the contract research firm PPD for $14.5 million. The firm was founded in 2006 by a well known group of biotech entrepreneuers and investors, including Rich Aldrich, founder of RA Capital, David Fisher, chief of dermatology at Massachusetts General Hospital, and Christoph Westphal, co-founder of Sirtris Pharmaceuticals. Having raised $17 million in seed and Series A financing from a syndicate of backers including ARCH Venture Partners, TVM Capital, and IDG Ventures (now Flybridge Capital Partners), the purchase price is unlikely to result in an exit for Magen’s backers.
Back in 2008, Magen inlicensed for an undisclosed sum a number of derm compounds from Eli Lilly that showed positive anti-inflammatory and anti-proliferative results in preclinical studies. It’s a good thing they did: those compounds were the primary reason for PPD’s interest in the biotech. The buy-out gives PPD an entrée into the specialist field of dermatology. In a press release announcing the news, PPD CEO Fred Eshelman noted that dermatologic treatments generally have a “more straightforward path to regulatory approval.” That’s certainly part of the logic behind moves of another specialist drug maker, Valeant, which is trying to brand itself as a derm power-house thanks to the recent acquisitions of Coria Laboratories, Dow, and DermaTech.
Related Articles
- PPD Sets Record and Distribution Dates for Spin-Off of Furiex Pharmaceuticals (eon.businesswire.com)
- More Downsizing (biojobblog.com)
- DARPA Backs Pulmatrix’s Lung Treatment, Adimab Scores More Pharma Partners, Semprus Secures $18M, & More Boston-Area Life Sciences News (xconomy.com)
- PPD Opens New Office in Beijing, China (eon.businesswire.com)
Comments»
No comments yet — be the first.